 |
|
|
| |
Pan-Genotypic Hepatitis C Treatment With Glecaprevir/Pibrentasvir Achieves Greatest Improvements in Quality-Adjusted Life-Years and Lifetime Risk Reductions in Liver-Related Morbidity and Mortality vs Standards of Care: A Cost-Utility Analysis
|
| |
| |
Reported by Jules Levin
American Association for the Study of Liver Diseases (AASLD) Congress, October 20-24, 2017, Washington, DC, USACONCLUSIONS
Sammy Saab1, Helene Parise2, Suchin Virabhak2, Scott Johnson2, Brett Pinsky3, Yuri Sanchez Gonzalez31David Geffen School of Medicine, UCLA, Los Angeles, CA; 2Medicus Economics, LLC, Boston, MA; 3Health Economics and Outcomes Research, AbbVie Inc., North Chicago, IL
|
| |
|
|
|
|
|
